In addition to luminal B cancers, many basal-like (ER-/PR-/HER2-) cancers have loss or mutation of PTEN and high PI3K activity [11,33], and some (though not all) basal cancers can reactivate the ER in response to GFR inhibition [48]. This evidence concerns the gene ESR1 and cancer.